Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
24
12
2021
accepted:
07
10
2022
pubmed:
14
10
2022
medline:
27
1
2023
entrez:
13
10
2022
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with vaccine efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 vaccine efficacy trials in the United Kingdom, we found that inter-individual variation in normalized antibody responses against SARS-CoV-2 spike and its receptor-binding domain (RBD) at 28 days after first vaccination shows genome-wide significant association with major histocompatibility complex (MHC) class II alleles. The most statistically significant association with higher levels of anti-RBD antibody was HLA-DQB1*06 (P = 3.2 × 10
Identifiants
pubmed: 36228659
doi: 10.1038/s41591-022-02078-6
pii: 10.1038/s41591-022-02078-6
pmc: PMC9873562
doi:
Substances chimiques
Antibodies, Viral
0
ChAdOx1 nCoV-19
B5S3K2V0G8
COVID-19 Vaccines
0
Histocompatibility Antigens Class II
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-157Subventions
Organisme : Medical Research Council
ID : MC_UU_00004/04
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204969/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 211153/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Investigateurs
Ana Cavey
(A)
Angela Minassian
(A)
Arabella Stuart
(A)
Baktash Khozoee
(B)
Brama Hanumunthadu
(B)
Brian Angus
(B)
Catherine C Smith
(CC)
Iain Turnbull
(I)
Jonathan Kwok
(J)
Katherine R W Emary
(KRW)
Liliana Cifuentes
(L)
Maheshi N Ramasamy
(MN)
Paola Cicconi
(P)
Adam Finn
(A)
Alastair C McGregor
(AC)
Andrea M Collins
(AM)
Andrew Smith
(A)
Anna L Goodman
(AL)
Christopher A Green
(CA)
Christopher J A Duncan
(CJA)
Christopher J A Williams
(CJA)
Daniela M Ferreira
(DM)
David P J Turner
(DPJ)
Emma C Thomson
(EC)
Helen Hill
(H)
Katrina Pollock
(K)
Mark Toshner
(M)
Patrick J Lillie
(PJ)
Paul Heath
(P)
Rajeka Lazarus
(R)
Rebecca K Sutherland
(RK)
Ruth O Payne
(RO)
Saul N Faust
(SN)
Tom Darton
(T)
Vincenzo Libri
(V)
Rachel Anslow
(R)
Samuel Provtsgaard-Morys
(S)
Thomas Hart
(T)
Amy Beveridge
(A)
Syed Adlou
(S)
Informations de copyright
© 2023. The Author(s).
Références
COVID-19 Map. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html
Taylor, L. Covid-19: true global death toll from pandemic is almost 15 million, says WHO. BMJ 377, o1144 (2022).
doi: 10.1136/bmj.o1144
Polack, F. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
doi: 10.1016/S0140-6736(20)32661-1
Pritchard, E. et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat. Med. 27, 1370–1378 (2021).
doi: 10.1038/s41591-021-01410-w
Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585–594 (2021).
doi: 10.1056/NEJMoa2108891
Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646–1657 (2021).
doi: 10.1016/S0140-6736(21)00677-2
Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474–1484 (2021).
doi: 10.1056/NEJMoa2109072
Bar-On, Y. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 385, 1393–1400 (2021).
doi: 10.1056/NEJMoa2114255
Wei, J. et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 6, 1140–1149 (2021).
doi: 10.1038/s41564-021-00947-3
Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110–1115 (2020).
doi: 10.1126/science.abe2402
Khoury, D. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
doi: 10.1038/s41591-021-01377-8
Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040 (2021).
Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417–422 (2021).
Newport, M. J. et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5, 122–129 (2004).
doi: 10.1038/sj.gene.6364051
Milich, D. R. & Leroux-Roels, G. G. Immunogenetics of the response to HBsAg vaccination. Autoimmun. Rev. 2, 248–257 (2003).
doi: 10.1016/S1568-9972(03)00031-4
Png, E. et al. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum. Mol. Genet. 20, 3893–3898 (2011).
doi: 10.1093/hmg/ddr302
Zhang, Z. et al. Host genetic determinants of hepatitis B virus infection. Front. Genet. 10, 696 (2019).
doi: 10.3389/fgene.2019.00696
Nishida, N. et al. Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology 68, 848–858 (2018).
doi: 10.1002/hep.29876
O’Connor, D. et al. Common genetic variations associated with the persistence of immunity following childhood immunization. Cell Rep. 27, 3241–3253 (2019).
doi: 10.1016/j.celrep.2019.05.053
Ovsyannikova, I. G., Pankratz, V. S., Vierkant, R. A., Jacobson, R. M. & Poland, G. A. Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine 30, 2146–2152 (2012).
doi: 10.1016/j.vaccine.2012.01.038
Clifford, H. D. et al. Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine 30, 6180–6185 (2012).
doi: 10.1016/j.vaccine.2012.07.063
Suzuki, T., Yamauchi, K., Kuwata, T. & Hayashi, N. Characterization of hepatitis B virus surface antigen-specific CD4
doi: 10.1046/j.1440-1746.2001.02530.x
Hohler, T. et al. C4A deficiency and nonresponse to hepatitis B vaccination. J. Hepatol. 37, 387–392 (2002).
doi: 10.1016/S0168-8278(02)00205-2
COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).
Kousathanas, A. et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature 607, 97–103 (2022).
doi: 10.1038/s41586-022-04576-6
Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2020).
doi: 10.1038/s41586-020-03065-y
Gonzalez-Galarza, F. F. et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 43, D784–D788 (2015).
doi: 10.1093/nar/gku1166
Siebold, C. et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc. Natl Acad. Sci. USA 101, 1999–2004 (2004).
doi: 10.1073/pnas.0308458100
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
doi: 10.1038/s41586-021-03819-2
Haralambieva, I. H. et al. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. Hum. Genet. 136, 421–435 (2017).
doi: 10.1007/s00439-017-1768-9
Milne, G. et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir. Med. 9, 1450–1466 (2021).
Gonzalez-Galarza, F. F. et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 48, D783–D788 (2020).
Hurley, C. et al. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. HLA 95, 516–531 (2020).
doi: 10.1111/tan.13811
Hammer, C. et al. Amino acid variation in HLA class II proteins is a major determinant of humoral response to common viruses. Am. J. Hum. Genet. 97, 738–743 (2015).
Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. Nat. Rev. Immunol. 18, 325–339 (2018).
doi: 10.1038/nri.2017.143
Nishida, N. et al. Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines. Sci. Rep. 11, 3703 (2021).
Somogyi, E. et al. A peptide vaccine candidate tailored to individuals’ genetics mimics the multi-targeted T cell immunity of COVID-19 convalescent subjects. Front. Genet. 12, 684152 (2021).
Trowsdale, J. & Knight, J. C. Major histocompatibility complex genomics and human disease. Annu. Rev. Genomics Hum. Genet. 14, 301–323 (2013).
doi: 10.1146/annurev-genom-091212-153455
Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467–478 (2020).
doi: 10.1016/S0140-6736(20)31604-4
Li, G. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet 399, 2212–2225 (2022).
doi: 10.1016/S0140-6736(22)00770-X
Stuart, A. S. V. et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 399, 36–49 (2022).
doi: 10.1016/S0140-6736(21)02718-5
Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856–869 (2021).
doi: 10.1016/S0140-6736(21)01694-9
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
doi: 10.1086/519795
McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).
doi: 10.1038/ng.3643
Luo, Y. et al. A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nat. Genet. 53, 1504–1516 (2021).
doi: 10.1038/s41588-021-00935-7
Stephens, M., Smith, N. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978–989 (2001).
doi: 10.1086/319501
Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nat. Methods 19, 679–682 (2022).
doi: 10.1038/s41592-022-01488-1
Trück, J. et al. The zwitterionic type I Streptococcus pneumoniae polysaccharide does not induce memory B cell formation in humans. Immunobiology 218, 368–372 (2013).
doi: 10.1016/j.imbio.2012.05.008
Clutterbuck, E. A. et al. Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin. Vaccin. Immunol. 15, 182–193 (2008).
doi: 10.1128/CVI.00336-07
Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011).
doi: 10.1016/j.ajhg.2010.11.011
Fay, M. P. & Shaw, P. A. Exact and asymptotic weighted logrank tests for interval censored data: the interval R package. J. Stat. Softw. 36, 1–34 (2010).
doi: 10.18637/jss.v036.i02
Therneau, T. M. & Grambsch, P. M. A Package for Survival Analysis in S (Mayo Foundation, 1999); https://www.mayo.edu/research/documents/tr53pdf/doc-10027379
van der Wal, W. M. & Geskus, R. B. ipw: an R package for inverse probability weighting. J. Stat. Softw. 43, 1–23 (2011).
doi: 10.18637/jss.v043.i13
Aulchenko, Y. S., Ripke, S., Isaacs, A. & van Duijn, C. M. GenABEL: an R library for genome-wide association analysis. Bioinformatics 23, 1294–1296 (2007).
doi: 10.1093/bioinformatics/btm108